Autolus Therapeutics plc (AUTL) Guidance & Earnings Results
On 2026-08-11 Autolus Therapeutics plc raised guidance: "FY2026 revenue guidance raised to $140-150M from…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUTLAutolus Therapeutics plcFollow AUTL — free
—
Price chart with a free account
- Market cap
- 409.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 11 Aug 26 | Raised | FY2026 revenue guidance raised to $140-150M from $120-135M · full year |
| 14 May 26 | Reaffirmed | FY2026 AUCATZYL net product revenue $120-135M (from $74M in 2025); continued positive gross margin · full year |
| 27 Mar 26 | Raised | FY2026 AUCATZYL net product revenue $120-135M; shift to positive gross margin in 2026 · full year |
Autolus Therapeutics plc — questions
- What guidance did Autolus Therapeutics plc give?
- On 2026-08-11: "FY2026 revenue guidance raised to $140-150M from $120-135M"
- When does Autolus Therapeutics plc report earnings?
- Autolus Therapeutics plc's next earnings report is expected on 2026-11-10.
Every figure on this page comes from Autolus Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.